169 related articles for article (PubMed ID: 28254655)
21. Evaluation of inhaler technique and patient satisfaction with fixed-combination budesonide/formoterol dry-powder inhaler in chronic obstructive pulmonary disease (COPD): data on real-life clinical practice in Turkey.
Öztürk C; Kaya A; Bilgin C; Yücesoy L; İkidağ B; Demirel M; Başlılar Ş; Şaylan B; Senol T; Ağanoğlu S; Can G; Doğrul MI; Çam M; Erdoğan N; Batum Ö; Turan MO; Demir C; Torun Ş; Cirit M; Turan M; Keleşoğlu A; Yaşar S; Uzunay Ö; Melek K; Altıparmak O
Tuberk Toraks; 2012; 60(4):301-13. PubMed ID: 23289459
[TBL] [Abstract][Full Text] [Related]
22. Ex-vivo product performance of Diskus and Turbuhaler inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease.
Burnell PK; Small T; Doig S; Johal B; Jenkins R; Gibson GJ
Respir Med; 2001 May; 95(5):324-30. PubMed ID: 11392571
[TBL] [Abstract][Full Text] [Related]
23. Ventolin Diskus and Inspyril Turbuhaler: an in vitro comparison.
Broeders ME; Molema J; Burnell PK; Folgering HT
J Aerosol Med; 2005; 18(1):74-82. PubMed ID: 15741776
[TBL] [Abstract][Full Text] [Related]
24. In-vitro intra- and inter-inhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler.
Tarsin W; Assi KH; Chrystyn H
J Aerosol Med; 2004; 17(1):25-32. PubMed ID: 15120010
[TBL] [Abstract][Full Text] [Related]
25. [CHARACTERISTICS OF BUDEFORU
Kondo T; Tanigaki T; Hibino M; Tajiri S; Horiuchi S; Ohbayashi H
Arerugi; 2022; 71(1):37-41. PubMed ID: 35173123
[TBL] [Abstract][Full Text] [Related]
26. Effect of maximum inhalation flow and inhaled volume on formoterol drug deposition in-vitro from an Easyhaler® dry powder inhaler.
Abadelah M; Hazim F; Chrystyn H; Bagherisadeghi G; Rahmoune H; Larhrib H
Eur J Pharm Sci; 2017 Jun; 104():180-187. PubMed ID: 28351669
[TBL] [Abstract][Full Text] [Related]
27. The effect of exhalation before the inhalation of dry powder aerosol drugs on the breathing parameters, emitted doses and aerosol size distributions.
Farkas Á; Tomisa G; Kugler S; Nagy A; Vaskó A; Kis E; Szénási G; Gálffy G; Horváth A
Int J Pharm X; 2023 Dec; 5():100167. PubMed ID: 36824288
[TBL] [Abstract][Full Text] [Related]
28. Dose emission and aerodynamic characterization of the terbutaline sulphate dose emitted from a Turbuhaler at low inhalation flow.
Abdelrahim ME; Assi KH; Chrystyn H
Pharm Dev Technol; 2013; 18(4):944-9. PubMed ID: 21981637
[TBL] [Abstract][Full Text] [Related]
29. Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction.
Broeders ME; Molema J; Hop WC; Folgering HT
J Aerosol Med; 2003; 16(2):131-41. PubMed ID: 12823907
[TBL] [Abstract][Full Text] [Related]
30. DuoResp
van der Palen J; Cerveri I; Roche N; Singh D; Plaza V; Gonzalez C; Patino O; Scheepstra I; Safioti G; Backer V
J Asthma; 2020 Oct; 57(10):1110-1118. PubMed ID: 31293211
[No Abstract] [Full Text] [Related]
31. Low-Dose Budesonide/Formoterol Counteracts Airway Inflammation and Improves Lung Function in Chronic Obstructive Pulmonary Disease.
Hakim A; Khan Y; Esteban I; Meah S; Miller-Larsson A; Barnes PJ; Usmani OS
Am J Respir Crit Care Med; 2019 Mar; 199(5):662-664. PubMed ID: 30540486
[No Abstract] [Full Text] [Related]
32. A randomized, double-blinded, double-dummy efficacy and safety study of budesonide-formoterol Spiromax® compared to budesonide-formoterol Turbuhaler® in adults and adolescents with persistent asthma.
Virchow JC; Rodriguez-Roisin R; Papi A; Shah TP; Gopalan G
BMC Pulm Med; 2016 Mar; 16():42. PubMed ID: 26987997
[TBL] [Abstract][Full Text] [Related]
33. Clinical equivalence of budesonide dry powder inhaler and pressurized metered dose inhaler.
Srichana T; Juthong S; Thawithong E; Supaiboonpipat S; Soorapan S
Clin Respir J; 2016 Jan; 10(1):74-82. PubMed ID: 25043636
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease.
Zhong N; Zheng J; Wen F; Yang L; Chen P; Xiu Q; Yao W; Sun T; Zhao Z; Shen H; Shi Y; Lin J; Li Q
Curr Med Res Opin; 2012 Feb; 28(2):257-65. PubMed ID: 22046961
[TBL] [Abstract][Full Text] [Related]
35. Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results.
Fukuchi Y; Samoro R; Fassakhov R; Taniguchi H; Ekelund J; Carlsson LG; Ichinose M
Respirology; 2013 Jul; 18(5):866-73. PubMed ID: 23551359
[TBL] [Abstract][Full Text] [Related]
36. Narrative Review of the Role of Patient-Reported Outcomes and Inhaler Handling Errors in the Control of Asthma and COPD.
De Simón Gutiérrez R; Castro RP
Curr Allergy Asthma Rep; 2022 Nov; 22(11):151-161. PubMed ID: 36087251
[TBL] [Abstract][Full Text] [Related]
37. Daily inhaled flow profiles and drug release from dry powder inhalers in patients with bronchial asthma.
Tajiri S; Kondo T; Tanigaki T; Hibino M; Asano K
Respir Med; 2022 Sep; 201():106950. PubMed ID: 35963030
[TBL] [Abstract][Full Text] [Related]
38. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD.
Derom E; Strandgården K; Schelfhout V; Borgström L; Pauwels R
Respir Med; 2007 Sep; 101(9):1931-41. PubMed ID: 17544264
[TBL] [Abstract][Full Text] [Related]
39. Exhalation immediately before inhalation optimizes dry powder inhaler use.
Kondo T; Hibino M; Tanigaki T; Ohe M; Kato S
J Asthma; 2015; 52(9):935-9. PubMed ID: 26513654
[TBL] [Abstract][Full Text] [Related]
40. [The variability of peak inspiratory flow (PIF) on valves imitating dry powder inhalers resistance during asthma and COPD exacerbations].
Grabowski M; Barg W; Chmielowicz B; Kopeć A; Panaszek B
Pneumonol Alergol Pol; 2007; 75(4):324-30. PubMed ID: 18080981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
